A detailed history of Thrivent Financial For Lutherans transactions in Incyte Corp stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 7,332 shares of INCY stock, worth $525,851. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,332
Previous 7,475 1.91%
Holding current value
$525,851
Previous $453,000 7.06%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$57.33 - $68.61 $8,198 - $9,811
-143 Reduced 1.91%
7,332 $485,000
Q2 2024

Aug 13, 2024

SELL
$51.18 - $63.75 $767,546 - $956,058
-14,997 Reduced 66.74%
7,475 $453,000
Q1 2024

May 14, 2024

BUY
$56.55 - $66.59 $748,891 - $881,851
13,243 Added 143.49%
22,472 $1.28 Million
Q4 2023

Feb 14, 2024

SELL
$52.16 - $64.19 $8,815 - $10,848
-169 Reduced 1.8%
9,229 $579,000
Q3 2023

Nov 14, 2023

SELL
$57.77 - $65.93 $3,755 - $4,285
-65 Reduced 0.69%
9,398 $543,000
Q2 2023

Aug 14, 2023

SELL
$60.95 - $75.51 $3,717 - $4,606
-61 Reduced 0.64%
9,463 $589,000
Q1 2023

May 17, 2023

BUY
$70.23 - $86.01 $113,491 - $138,992
1,616 Added 20.44%
9,524 $688,000
Q4 2022

Feb 08, 2023

SELL
$67.18 - $84.11 $66,441 - $83,184
-989 Reduced 11.12%
7,908 $635,000
Q3 2022

Nov 14, 2022

SELL
$66.18 - $82.86 $7,676 - $9,611
-116 Reduced 1.29%
8,897 $593,000
Q2 2022

Aug 16, 2022

BUY
$66.18 - $83.18 $2,250 - $2,828
34 Added 0.38%
9,013 $685,000
Q1 2022

May 13, 2022

SELL
$66.02 - $79.71 $834,426 - $1.01 Million
-12,639 Reduced 58.47%
8,979 $713,000
Q4 2021

Feb 16, 2022

BUY
$63.34 - $74.11 $794,473 - $929,561
12,543 Added 138.21%
21,618 $1.59 Million
Q3 2021

Nov 15, 2021

BUY
$68.67 - $84.02 $1,579 - $1,932
23 Added 0.25%
9,075 $624,000
Q2 2021

Aug 19, 2021

SELL
$79.87 - $87.53 $2,316 - $2,538
-29 Reduced 0.32%
9,052 $762,000
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $75,867 - $100,299
998 Added 12.35%
9,081 $738,000
Q4 2020

Feb 16, 2021

SELL
$80.74 - $97.7 $1.65 Million - $2 Million
-20,485 Reduced 71.71%
8,083 $703,000
Q3 2020

Nov 10, 2020

BUY
$85.07 - $109.69 $1.73 Million - $2.23 Million
20,294 Added 245.27%
28,568 $2.56 Million
Q2 2020

Aug 12, 2020

BUY
$74.18 - $108.93 $9,272 - $13,616
125 Added 1.53%
8,274 $860,000
Q4 2019

Feb 13, 2020

BUY
$73.04 - $95.72 $10,590 - $13,879
145 Added 1.81%
8,149 $712,000
Q2 2019

Aug 13, 2019

BUY
$73.52 - $88.7 $5,661 - $6,829
77 Added 0.97%
8,004 $680,000
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $15,190 - $21,072
239 Added 3.11%
7,927 $682,000
Q4 2018

Feb 15, 2019

BUY
$58.5 - $69.94 $7,897 - $9,441
135 Added 1.79%
7,688 $489,000
Q3 2018

Nov 15, 2018

BUY
$61.75 - $74.23 $10,250 - $12,322
166 Added 2.25%
7,553 $522,000
Q2 2018

Aug 14, 2018

BUY
$60.85 - $83.98 $4,685 - $6,466
77 Added 1.05%
7,387 $495,000
Q1 2018

May 08, 2018

BUY
$83.06 - $100.98 $15,283 - $18,580
184 Added 2.58%
7,310 $609,000
Q4 2017

Feb 14, 2018

BUY
$93.56 - $116.6 $31,436 - $39,177
336 Added 4.95%
7,126 $675,000
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $741,128 - $938,853
6,790
6,790 $793,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.